Table 1 Clinical trial details

From: Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

Study

Phase

Intervention

N

evaluable patients

% Total

Median follow-up (years)a

N

survival eventsb

S9321

3

VBMCP vs.

Mel+TBI+SCT

788

27.2

9.0

481

S0204

2

Thal→ Tandem SCT→Thalidomide maintenance

130

4.5

9.9

53

S0232

3

Dex+/−Len

176

6.1

6.7

89

E9486

3

VBMCP vs. VBMCP+IFN α vs. VBMCP+Cyclophosphamide

648

22.4

12.8

492

E5A93

3

VBMCP vs. VBMCP+IFN α or Cyclophosphamide

222

7.7

9.9

164

E1A00

3

Dex+/−Thal

205

7.1

8.0

128

E2A02

2

Bortezomib

40

1.4

6.0

25

E4A03

3

Len+low vs. high dose Dex

402

13.9

7.0

191

E1A06

3

Mel, Prednisone+Thal vs. Len

285

9.8

4.9

159

  1. VBMCP Vincristine/BCNU/Melphalan/Cyclophosphamide/Prednisone, Mel myeloablative melphalan, TBI total body irradiation, SCT stem cell transplant, Len lenalidomide, Thal thalidomide, Dex dexamethasone, IFN interferon
  2. aIn the absence of censoring
  3. bFollow-up was censored at 6 years for all studies
Back to article page